Compare · AIKI vs SBTX
AIKI vs SBTX
Side-by-side comparison of AIkido Pharma Inc. (AIKI) and Silverback Therapeutics Inc. (SBTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIKI and SBTX operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
- SBTX has more recent analyst coverage (6 ratings vs 1 for AIKI).
- Company
- AIkido Pharma Inc.
- Silverback Therapeutics Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 0
- Recent ratings
- 1
- 6
AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.
Silverback Therapeutics Inc.
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Latest AIKI
- SEC Form SC 13D filed by AIkido Pharma Inc.
- SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)
- Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)
- Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)
- Wool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)
- Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)
- AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update
- Hayes Anthony bought $8,012 worth of shares (4,000 units at $2.00) (SEC Form 4)
- Wool Kyle Michael bought $8,122 worth of shares (4,000 units at $2.03) (SEC Form 4)
- Devall Christopher Franklin bought $2,278 worth of shares (1,000 units at $2.28), increasing direct ownership by 5% to 23,033 units (SEC Form 4)
Latest SBTX
- SEC Form SC 13G/A filed by Silverback Therapeutics Inc. (Amendment)
- Lowenthal Richard E gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 20% to 4,126,822 units (SEC Form 4)
- SEC Form 4 filed by Karas Eric
- Tanimoto Sarina gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 24% to 3,276,854 units (SEC Form 4)
- SEC Form 4 filed by Dorsey Brian
- SEC Form 4 filed by Chakma Justin
- SEC Form 4 filed by Scott Kathleen D.
- SEC Form 4 filed by Fitzpatrick Alexander A
- SEC Form 10-Q filed by Silverback Therapeutics Inc.
- Silverback Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits